novo-products-patients-26.html
Novo Annual Review 2016
27 / 71
a unique approach to venture
investments
n ovo ventures is a specialised life science venture capital investor. we focus on building and realising financial value in our portfolio. in addition to generating financial return, we strive to invest in
companies
that develop drugs, medical devices and diagnostics that can improve the health and lives of people around the world.
novo
a/s? approach to venture capital
investments
is unique due to our special ownership structure.
novo
has significant shareholdings in
novo
nordisk a/s and
novo
zymes a/s, but our venture
investments
are fully independent of the two major
novo
group
companies
. our venture
investments
are structured as an open evergreen fund with
novo
as the only investor. this unique funding structure allows us to assume a long-term perspective when we make our
investments
. an international investor with people on the ground in copenhagen, london, san francisco and boston,
novo
is positioned to reach the major global life science hubs and can quickly respond to new, interesting investment opportunities wherever they emerge. our team also supports our portfolio
companies
through participation on the board of directors and by leveraging the experience gained from our diverse life science portfolio. a strong track record during our 17 years in the business, we have invested dkk 10 billion in 138
companies
and successfully exited 44
companies
? primarily through trade sales to large pharmaceutical and medical device
companies
, and through ipos that have provided liquidity. today, we have a diversified portfolio of life science
companies
and a history of successful exits that have delivered positive financial results. with annual
investments
of over dkk 2 billion in 2016,
novo
?s ventures
investments
have reached their highest level ever. investment approach for 2017 and beyond
novo
is expanding its venture
investments
in both private and public market investing. in 2017, we will continue with a high level of investing and allocating more resources to our teams in copenhagen, san francisco and boston. while increasing the level of private investing, we will have a greater focus on public
investments
. we will continue to focus on development and regulatory stage
companies
that address unmet therapeutic needs. within medtech investing, we will be deploying specific resources to identify new opportunities. we will continue to focus on us-marketed, revenue-stage, high-growth
companies
that use innovation to address underserved patient populations. for more information about
novo
?s ventures
investments
, please visit
novo
.dk geographical allocation by % invested per country the loaded embrace between a dendritic cell and a lymphocyte is the focus for the next generation immunotherapeutics. source: nature biotechnology. geographical allocation by number of
companies
93 ? usa 1 (in each) ? austria france netherlands sweden <1% ? austria sweden 3% ? switzerland 77% ? usa 8% ? denmark uk 1% ? canada finland france netherlands 2 ? canada 6 ? switzerland 14 ? uk 18 ? denmark
novo
ventures 27
dkk-billion-companies-28.html
